Constellation Pharmaceuticals Stock Forecast, Price & News

-0.31 (-1.36 %)
(As of 04/9/2021 12:00 AM ET)
Today's Range
Now: $22.50
50-Day Range
MA: $27.32
52-Week Range
Now: $22.50
Volume255,738 shs
Average Volume464,423 shs
Market Capitalization$1.08 billion
P/E RatioN/A
Dividend YieldN/A
Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Constellation Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CNST
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$8.23 per share


Net Income$-85,550,000.00


Market Cap$1.08 billion
Next Earnings Date5/5/2021 (Estimated)
OptionableNot Optionable


Is CNST Stock A Buy or Sell?
April 8, 2021 |
Constellation Pharmaceuticals (NASDAQ:CNST) Shares Up 2.9%
March 25, 2021 |
CNST Crosses Below Key Moving Average Level
February 24, 2021 |
Pharma Stock Ideas: Why BMO Is Recommending Regeneron, Constellation
January 25, 2021 |
CNST Feb 2021 30.000 call
January 19, 2021 |
CNST Jan 2021 25.000 put
December 21, 2020 |
See More Headlines


Overall MarketRank

1.15 out of 5 stars

Medical Sector

942nd out of 2,010 stocks

Pharmaceutical Preparations Industry

447th out of 769 stocks

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.31 (-1.36 %)
(As of 04/9/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNST News and Ratings via Email

Sign-up to receive the latest news and ratings for CNST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Constellation Pharmaceuticals (NASDAQ:CNST) Frequently Asked Questions

Is Constellation Pharmaceuticals a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Constellation Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Constellation Pharmaceuticals stock.
View analyst ratings for Constellation Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Constellation Pharmaceuticals?

Wall Street analysts have given Constellation Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Constellation Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Constellation Pharmaceuticals' next earnings date?

Constellation Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Constellation Pharmaceuticals

How were Constellation Pharmaceuticals' earnings last quarter?

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) released its quarterly earnings data on Tuesday, February, 23rd. The company reported ($0.79) EPS for the quarter, missing the Zacks' consensus estimate of ($0.74) by $0.05.
View Constellation Pharmaceuticals' earnings history

How has Constellation Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Constellation Pharmaceuticals' stock was trading at $32.57 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CNST shares have decreased by 30.9% and is now trading at $22.50.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CNST?

7 brokerages have issued 12-month target prices for Constellation Pharmaceuticals' shares. Their forecasts range from $20.00 to $75.00. On average, they anticipate Constellation Pharmaceuticals' stock price to reach $45.29 in the next year. This suggests a possible upside of 101.3% from the stock's current price.
View analysts' price targets for Constellation Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Constellation Pharmaceuticals' key executives?

Constellation Pharmaceuticals' management team includes the following people:
  • Mr. Jigar Raythatha, Pres, CEO & Director
  • Ms. Emma Reeve, Chief Financial Officer (Age 60, Pay $570.4k)
  • Dr. Adrian M. Senderowicz M.D., Sr. Advisor (Age 57, Pay $605.9k)
  • Dr. Danny Reinberg, Co-Founder
  • Dr. Yang Shi Ph.D., Co-Founder
  • Dr. David Allis, Co-Founder
  • Mr. Mohan Bala Ph.D., Chief Operating Officer
  • Dr. Patrick Trojer Ph.D., Sr. VP & Chief Scientific Officer (Age 48)
  • Mr. Ronald Aldridge, Sr. Director of Investor Relations (Age 67)
  • Kia Khaleghpour Ph.D., VP of Investor Relations & Communications

What is Jigar Raythatha's approval rating as Constellation Pharmaceuticals' CEO?

10 employees have rated Constellation Pharmaceuticals CEO Jigar Raythatha on Jigar Raythatha has an approval rating of 100% among Constellation Pharmaceuticals' employees. This puts Jigar Raythatha in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Constellation Pharmaceuticals' key competitors?

What other stocks do shareholders of Constellation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Constellation Pharmaceuticals investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Applied Materials (AMAT), Inovio Pharmaceuticals (INO), Intel (INTC), NVIDIA (NVDA), Pfizer (PFE), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and AT&T (T).

When did Constellation Pharmaceuticals IPO?

(CNST) raised $80 million in an initial public offering on Thursday, July 19th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and BMO Capital Markets served as the underwriters for the IPO and Oppenheimer was co-manager.

What is Constellation Pharmaceuticals' stock symbol?

Constellation Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNST."

How do I buy shares of Constellation Pharmaceuticals?

Shares of CNST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Constellation Pharmaceuticals' stock price today?

One share of CNST stock can currently be purchased for approximately $22.50.

How much money does Constellation Pharmaceuticals make?

Constellation Pharmaceuticals has a market capitalization of $1.08 billion. The company earns $-85,550,000.00 in net income (profit) each year or ($3.04) on an earnings per share basis.

How many employees does Constellation Pharmaceuticals have?

Constellation Pharmaceuticals employs 154 workers across the globe.

What is Constellation Pharmaceuticals' official website?

The official website for Constellation Pharmaceuticals is

Where are Constellation Pharmaceuticals' headquarters?

Constellation Pharmaceuticals is headquartered at 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142.

How can I contact Constellation Pharmaceuticals?

Constellation Pharmaceuticals' mailing address is 215 FIRST STREET SUITE 200, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-714-0555 or via email at [email protected]

This page was last updated on 4/10/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.